Health-Related Quality-of-Life Outcomes with Actinium-225-Prostate-Specific Membrane Antigen-617 Therapy in Patients with Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer

AIMS: Actinium-225 ((225)Ac) labeled prostate-specific membrane antigen (PSMA)-617 is a novel treatment modality in the management of metastatic castration-resistant prostate cancer (mCRPC). The present study was conducted to assess the impact of (225)Ac-PSMA-617 therapy on the quality-of-life of pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Satapathy, Swayamjeet, Mittal, Bhagwant Rai, Sood, Ashwani, Das, Chandan Krushna, Singh, Shrawan Kumar, Mavuduru, Ravimohan Suryanarayan, Bora, Girdhar Singh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905268/
https://www.ncbi.nlm.nih.gov/pubmed/33642753
http://dx.doi.org/10.4103/ijnm.IJNM_130_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905268/
https://www.ncbi.nlm.nih.gov/pubmed/33642753
http://dx.doi.org/10.4103/ijnm.IJNM_130_20

Ejemplares similares